We asked our team how they’d describe Dianthus, take a look at some of their responses! For the second year in a row, the top 3 words were Open, Collaborative, and Supportive, with two new additions, Motivated and Ambitious! As our company evolves, we aim to continue cultivating an environment where our employees thrive and #GrowTogether. Visit dianthustx.com/careers to learn more about our mission, culture, and opportunities to join our team! #biotech #teamwork #employeeengagement
Dianthus Therapeutics, Inc.
Biotechnology Research
New York City, New York 4,631 followers
Unlocking the full potential of complement therapeutics through the power of selectivity.
About us
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
- Website
-
https://dianthustx.com
External link for Dianthus Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York City, New York
- Type
- Public Company
Locations
-
Primary
7 Times Square, Floor 43
New York City, New York, US
-
203 Crescent St
Building 4, Suite 205
Waltham, Massachusetts 02453, US
Employees at Dianthus Therapeutics, Inc.
Updates
-
Dianthus Therapeutics, Inc. reposted this
Adaptable Clinical Operations Leader optimizing clinical research careers and medical products | Creating a community dedicated to delivering better outcomes to patients, physicians, and teams
Dianthus gets it - from 100% remote work flexibility to summer & winter shutdowns. If we’ve worked together & you’re looking for a new role in biostats, DM me.
🚨 Hot Job Alert! 🚨 We are #hiring a Senior Director, Biostatistics. You will be developing and executing our #biostats strategy for multiple clinical programs as we advance the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/edk9Fb4a
-
🚨 Hot Job Alert! 🚨 We are #hiring a Senior Director, Biostatistics. You will be developing and executing our #biostats strategy for multiple clinical programs as we advance the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/edk9Fb4a
-
We are excited to announce two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki. June 29, 2024, 14:10 EEST DNTH103, Investigational Therapy for Generalised Myasthenia Gravis Session: Muscle and Neuromuscular Junction Disorder 1; Presentation Number: EPR-118 June 30, 2024, 14:25 EEST DNTH103: Preventing Nerve Damage in a CIDP Model via Sustained Complement Inhibition Session: Muscle and Neuromuscular Junction Disorder 2; Presentation Number: EPR-243 These posters will be made available after they are presented on the Dianthus website: https://lnkd.in/gZz2x_tw DNTH103 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide. #ean2024 #neurology
-
We are always looking for the most passionate and innovative individuals, so our team comes from all over the nation! With our combination of #remote and #hybrid roles, our team now spans across 11 states, including two team members across the pond. Look out for our Hot Job Alerts and visit dianthustx.com/careers to learn more about how we #GrowTogether! #hiring #biotechjobs #GrowWithUs
-
As a chronic neuromuscular disease, #MyastheniaGravis causes weakness in the voluntary muscles. It affects both men and women and occurs across all racial and ethnic groups. We are #MGStrong and committed to advancing the next generation of #ComplementTherapeutics with the potential to treat patients living with generalized Myasthenia Gravis.
-
A big thanks to our CPO Kristina M. for driving our Learning & Development, alongside Results By Design®, LLC and Ted Higgins who facilitated our recent training on the Fundamentals of Presentation Design! It was a great opportunity to discuss tactics on how to be more efficient and compelling presenters. #biotech #skillbuilding #TeamDianthus
-
We are excited to announce we received FDA clearance of our Phase 2 Investigational New Drug (IND) application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy (MMN). Top-line results are expected to be available in the second half of 2026. Learn more: https://lnkd.in/ggZZeSfZ #biotech #MMN
-
June is #MyastheniaGravis (MG) Awareness Month! At Dianthus, we are raising awareness for the advocates, patients, and caregivers in the MG community. #MGStrong